Amgen

This Phase 3 trial is testing whether a targeted immunotherapy drug called blinatumomab, given alongside low-intensity chemotherapy, works better than standard chemotherapy for older adults (55+) with a specific type of acute lymphoblastic leukemia (ALL). The study involves 303 p…

This study tests an experimental drug called rocatinlimab in adults with moderate-to-severe asthma. The goal is to see if it can reduce the number of asthma attacks. Participants continue their usual asthma medications while receiving the drug or a placebo. The study involves abo…

This early-stage study tests a new drug, maridebart cafraglutide, to see if it helps people with type 2 diabetes use insulin better. About 56 adults on metformin will receive either the drug or a placebo. The main goal is to measure changes in insulin sensitivity after 25 weeks.

This study tests whether a new drug, ABP 692, works as well as the approved drug Ocrevus for people with relapsing-remitting multiple sclerosis (RRMS). About 152 adults with RRMS will receive either ABP 692 or Ocrevus to compare how the drugs move through the body and how well th…

This early-stage trial is testing a new drug called anvumetostat, given together with other standard chemotherapy drugs, for people with advanced cancers of the digestive system (stomach, bile ducts, or pancreas) that have a specific genetic change called MTAP deletion. The main …

This study tests a new drug called anvumetostat in people with a specific genetic form of advanced non-small cell lung cancer (MTAP-deleted NSCLC) that has worsened after prior treatment. The main goals are to see if the drug shrinks tumors and to check its safety. About 61 parti…

This study tests a subcutaneous (under the skin) injection of blinatumomab for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or minimal residual disease. The goal is to see if this new method is safe and effective. About 181 adults and adolescents…

This study tests a new drug called anvumetostat, alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that lack the MTAP gene. The goal is to find the safest dose and see if it shrinks tumors. About 329 people will take part across multiple phases.

This early-stage trial is testing a new drug called anvumetostat, alone or with other cancer drugs, in about 49 adults with advanced lung or chest tumors that lack a gene called MTAP. The main goals are to find the safest dose and to see what side effects occur. Researchers will …

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…

This study tests if Prolia can improve bone density in people whose bones have weakened from taking steroids (glucocorticoids). About 102 adults in China will receive the drug and be monitored for 12 months. The main goal is to see if bone mass in the lower spine increases.

This study tests a drug called romosozumab against standard bone-strengthening medicines (bisphosphonates) in children and teens with osteogenesis imperfecta, a condition that causes fragile bones and frequent fractures. The goal is to see if romosozumab can reduce the number of …

This early-phase trial tests a combination of three drugs—tarlatamab, YL201, and durvalumab—in 29 adults with extensive stage small cell lung cancer that has progressed after prior treatment. The main goal is to check safety and side effects, while also measuring how well the tum…

This study tests whether a new drug called xaluritamig helps people with advanced prostate cancer live longer compared to usual treatments (cabazitaxel or another hormone therapy). The trial includes about 700 adults whose cancer has spread and no longer responds to hormone thera…

This study tests a subcutaneous (under the skin) injection of blinatumomab in children under 12 with relapsed/refractory or minimal residual disease positive B-cell acute lymphoblastic leukemia. The goal is to see if this easier-to-give form is safe and effective at achieving rem…

This study tests a drug called inebilizumab in 238 adults with myasthenia gravis, a condition that causes muscle weakness. The main goal is to see if the drug improves patients' ability to do daily activities over 26 weeks compared to a placebo. Participants must have specific an…

This phase 3 trial tests whether ABP 234, a biosimilar of the immunotherapy drug pembrolizumab (Keytruda), works as well as the original in people with advanced non-squamous non-small cell lung cancer who have not had prior treatment. About 315 participants will receive either AB…

This study looks at the long-term safety and tolerability of a drug called rocatinlimab for people with moderate-to-severe atopic dermatitis (eczema). It involves over 2,600 adults and teenagers who have already completed a previous rocatinlimab study. Researchers will monitor si…

This phase 3 trial compares the experimental drug AMG 510 (sotorasib) to the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. About 345 participants who have already received prior treatment are bein…

This phase 3 study tests whether tarlatamab, an experimental drug, can delay cancer progression or improve survival in people with limited-stage small-cell lung cancer who have finished chemoradiation without their cancer getting worse. About 404 participants will receive either …

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The main goal is to see if the drug can shrink tumors. Researchers will also monitor side effects and how long any response l…

This study tests whether ABP 234, a biosimilar to the cancer drug Keytruda, works the same in people with early-stage non-squamous lung cancer after surgery and chemotherapy. About 163 adults will receive either ABP 234 or Keytruda to compare how the drug behaves in the body. The…

This phase 2 trial is testing tarlatamab, an experimental drug given by IV, in 252 adults with small cell lung cancer that has worsened after platinum-based chemotherapy. The main goal is to see if the drug can shrink tumors (partial or complete response). Researchers will also m…

This early-stage trial is testing a new drug called tarlatamab, which helps the immune system find and attack cancer cells, when given together with standard chemotherapy and immunotherapy. The study includes about 184 people with extensive-stage small cell lung cancer who have n…

This study tests a drug called olpasiran in about 7,300 people with heart disease and high levels of a fatty particle called Lp(a). The goal is to see if olpasiran can lower the chance of heart attacks, urgent heart procedures, or death from heart disease compared to a placebo. P…

This study looks at how well the drug Prolia works for men with osteoporosis in mainland China. About 102 men aged 30 to 90 with weak bones will receive Prolia injections. The main goal is to see if bone density in the lower spine improves after 12 months of treatment.

This study tests a drug called blinatumomab in 18 children (ages 1 month to 18 years) in China whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatment. The goal is to see if the drug can bring about complete remission and to check for side ef…

This phase 3 trial tests an injectable drug called teprotumumab for people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging and discomfort. About 89 adults will receive either the drug or a placebo injection to see if it reduces eye bulging …

This study is testing a new drug called xaluritamig in men whose prostate cancer has returned after initial treatment but has not spread. The main goal is to see if the drug is safe and tolerable. About 50 participants will receive the drug, and researchers will monitor side effe…

This early-stage trial is checking whether maridebart cafraglutide, a new weight-loss drug, affects the heart's electrical activity. About 81 adults with overweight or obesity will receive the drug or a placebo, and their heart rhythms will be closely monitored. The main goal is …

This Phase 3 trial tests dazodalibep, a drug given by IV, in 651 people with moderate-to-severe Sjögren's syndrome. The goal is to see if it reduces disease activity and improves symptoms like dryness and fatigue. Participants receive either the drug or a placebo, and researchers…

This phase 3 trial is testing ABP 206, a biosimilar to the immunotherapy drug nivolumab (Opdivo), in 633 people with untreated advanced melanoma. The goal is to see if ABP 206 works just as well as nivolumab in shrinking tumors and extending life, while having a similar safety pr…

This phase 3 study compares tarlatamab, an experimental drug, to standard treatments in about 500 adults with small cell lung cancer that returned after initial chemotherapy. The main goal is to see if tarlatamab helps people live longer. Participants must have measurable disease…

This study tests a new medication, maridebart cafraglutide, to see if it helps adults with type 2 diabetes who are overweight or obese lose more weight than a placebo. About 1,100 participants will receive either the drug or a placebo for 72 weeks. The main goal is to measure the…

This phase 3 study tests whether erenumab (Aimovig), a monthly injection already approved for adults, can prevent migraines in children aged 6 to 17 with episodic migraine. About 457 participants receive either the drug or a placebo for 3 months. The main goal is to see if the dr…

This phase 2 study tests a drug called tarlatamab in 222 people with relapsed or refractory small cell lung cancer who have already tried at least two prior treatments. The goal is to see if tarlatamab can shrink tumors and how safe it is. Participants receive the drug through an…

This phase 3 trial is testing whether apremilast (Otezla) can safely and effectively treat moderate to severe plaque psoriasis in Japanese children and adolescents aged 6 to 17. The study involves 17 participants who take oral tablets for 16 weeks. The main goal is to see if thei…

This clinical trial is testing whether adding a targeted drug called bemarituzumab to standard chemotherapy and immunotherapy (nivolumab) helps people with advanced stomach or gastroesophageal junction cancer live longer. The study includes 515 adults whose tumors overexpress a p…

This study tests a new drug called maridebart cafraglutide to help adults in Japan with obesity lose weight. About 279 participants will receive either the drug or a placebo for 72 weeks. The main goals are to see how much weight they lose and if at least 5% of body weight is los…

This phase 3 trial tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer than durvalumab alone. About 563 participants who have already completed initial chemotherapy plus durvalumab will be randomly assigned to one of …

This study tests a drug called inebilizumab to see if it can prevent flare-ups in people with IgG4-related disease, a rare condition that causes swelling and damage in organs. About 135 adults who have had recent flare-ups are taking part. The main goal is to see how long it take…

This study tests a new drug called bemarituzumab, given together with chemotherapy and an immunotherapy drug (nivolumab), in 72 adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The main goals are to check safety and see if the co…

This Phase 2 study tests a new injectable drug called maridebart cafraglutide in 409 adults with type 2 diabetes. The main goal is to see if it improves blood sugar control compared to a placebo. Researchers will also check if it helps with weight loss. The trial is active but no…

This study looks at the long-term safety of inebilizumab (UPLIZNA) in people with neuromyelitis optica spectrum disorder (NMOSD). Researchers will measure immune markers like immunoglobulins and B-cells in 32 participants during treatment and after stopping. The goal is to unders…

This early-phase study is testing a new drug, tarlatamab, in 269 people with small cell lung cancer that has worsened after standard treatment. Tarlatamab is designed to help the body's immune cells find and attack cancer cells. The main goals are to check the drug's safety, find…

This study is testing the safety of the drug apremilast (Otezla) in 51 children and teens aged 6 to 17 with mild to moderate plaque psoriasis. Participants take the drug as an oral tablet, and researchers monitor for side effects, growth, and development. The goal is to see if th…

This early-phase trial tests a drug called sotorasib, alone or with other cancer treatments, in adults with advanced solid tumors that have a specific KRAS G12C mutation. The main goals are to check safety and how the body handles the drug. About 610 participants are enrolled acr…

This study tests a new drug called maridebart cafraglutide to help adults with obesity or overweight lose weight. About 3853 people will take either the drug or a placebo for 72 weeks. The main goal is to see how much weight they lose and if it is safe.

This early-phase study tests a new treatment called AMG 119 for adults with small cell lung cancer that has returned or not responded to standard chemotherapy. The treatment uses specially engineered immune cells (CAR T cells) designed to find and attack cancer cells. The main go…

This study tests whether giving evolocumab, a powerful cholesterol-lowering drug, very early during a heart attack hospital stay can reduce the chance of another heart attack, stroke, or death. About 6,000 adults hospitalized for a heart attack are randomly assigned to receive ev…

This phase 4 study tests the drug XGEVA (denosumab) in 36 Chinese adults and teens with giant cell tumor of bone, a rare but aggressive bone tumor. Participants receive injections every 4 weeks. The goal is to see if the drug shrinks tumors or helps make surgery easier. The study…

This early-stage trial is testing an experimental drug called AMG 691 in 21 healthy volunteers and people with mild-to-moderate asthma. The main goal is to see if the drug is safe and how the body processes it. Participants receive either the drug or a placebo as an injection und…

This phase 3 study tests rocatinlimab, an injectable drug, against a placebo in 469 adults with prurigo nodularis—a condition causing intense itching and hard bumps on the skin. Participants had not gotten enough relief from topical treatments. The main goal is to see if the drug…

This study tests whether romiplostim can prevent chemotherapy delays or dose reductions caused by low platelet counts in people with lung, ovarian, or breast cancer. About 145 adults will receive either romiplostim or a placebo alongside their chemotherapy. The goal is to help pa…

This study tests an experimental drug called dazodalibep in 434 adults with moderate-to-severe Sjögren's syndrome, an autoimmune disease causing dryness, fatigue, and pain. Participants receive either the drug or a placebo to see if it improves symptoms like dry eyes and mouth. T…

This early-stage study compares two forms of the cholesterol-lowering drug evolocumab in 400 healthy adults aged 18 to 60. Participants receive a single injection of one version, and researchers measure how much drug gets into the blood and how long it stays. The goal is to see i…

This early-stage study tests how two different injection versions of the experimental drug AMG 133 are absorbed by the body in 349 adults with overweight or obesity. Participants receive a single dose, and researchers measure drug levels and safety. The goal is not to treat obesi…